JP2005519941A - 結核の管理のために有用な医薬組成物の製造方法 - Google Patents

結核の管理のために有用な医薬組成物の製造方法 Download PDF

Info

Publication number
JP2005519941A
JP2005519941A JP2003574100A JP2003574100A JP2005519941A JP 2005519941 A JP2005519941 A JP 2005519941A JP 2003574100 A JP2003574100 A JP 2003574100A JP 2003574100 A JP2003574100 A JP 2003574100A JP 2005519941 A JP2005519941 A JP 2005519941A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tuberculosis
mycobacterium
management
prepared according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574100A
Other languages
English (en)
Japanese (ja)
Inventor
カーマー，バクレシュ，マファトラル
Original Assignee
カーマー，バクレシュ，マファトラル
モディ，ラジヴ，インドラヴァーダン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーマー，バクレシュ，マファトラル, モディ，ラジヴ，インドラヴァーダン filed Critical カーマー，バクレシュ，マファトラル
Publication of JP2005519941A publication Critical patent/JP2005519941A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003574100A 2002-03-08 2003-03-04 結核の管理のために有用な医薬組成物の製造方法 Pending JP2005519941A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN236MU2002 2002-03-08
PCT/IB2003/000801 WO2003075824A2 (en) 2002-03-08 2003-03-04 Process of manufacturing pharmaceutical composition useful for management of tuberculosis

Publications (1)

Publication Number Publication Date
JP2005519941A true JP2005519941A (ja) 2005-07-07

Family

ID=27799868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574100A Pending JP2005519941A (ja) 2002-03-08 2003-03-04 結核の管理のために有用な医薬組成物の製造方法

Country Status (5)

Country Link
JP (1) JP2005519941A (pt)
KR (1) KR20050008453A (pt)
AU (1) AU2003209533A1 (pt)
BR (1) BR0303367A (pt)
WO (1) WO2003075824A2 (pt)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤
JP2010523711A (ja) * 2007-04-12 2010-07-15 ジェニファー ライター， 結核のワクチンおよびその使用方法
JP2010531347A (ja) * 2007-06-28 2010-09-24 カディラ ファーマシューティカルズ リミテッド マイトジェン活性化プロテインキナーゼ調節剤
JP2014526451A (ja) * 2011-09-08 2014-10-06 ユニヴェルシテ・ドゥ・ボルドー マルビジン−３−ｏ−ベータ−グルコシド及びプロポリス抽出物を含む抗炎症組成物
JP2017524661A (ja) * 2014-08-18 2017-08-31 ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
BR0307262A (pt) * 2002-01-29 2006-12-19 Bakulesh Mafatlal Khamar método de prover profilaxia para tuberculose em indivìduos hiv positivos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567585A (en) * 1963-07-12 1971-03-02 Ciba Geigy Corp Process for obtaining bcg-cultures
JPS4843842B1 (pt) * 1970-07-17 1973-12-21

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤
JP2010523711A (ja) * 2007-04-12 2010-07-15 ジェニファー ライター， 結核のワクチンおよびその使用方法
JP2015038130A (ja) * 2007-04-12 2015-02-26 ジェニファー ライター， 結核のワクチンおよびその使用方法
JP2010531347A (ja) * 2007-06-28 2010-09-24 カディラ ファーマシューティカルズ リミテッド マイトジェン活性化プロテインキナーゼ調節剤
JP2014526451A (ja) * 2011-09-08 2014-10-06 ユニヴェルシテ・ドゥ・ボルドー マルビジン−３−ｏ−ベータ−グルコシド及びプロポリス抽出物を含む抗炎症組成物
JP2017524661A (ja) * 2014-08-18 2017-08-31 ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物

Also Published As

Publication number Publication date
KR20050008453A (ko) 2005-01-21
AU2003209533A1 (en) 2003-09-22
WO2003075824A3 (en) 2003-12-24
WO2003075824A2 (en) 2003-09-18
BR0303367A (pt) 2004-07-20
AU2003209533A8 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
Zbar et al. Immunotherapy of guinea pig cancer with BCG
JPH06501478A (ja) ブドウ膜炎の処置
NO311169B1 (no) Mykobakterium-vaksiner for behandling av langtids-autoimmune sykdommer
JP2012510497A (ja) ワクチンの生産方法
JP4527979B2 (ja) 癌を治療する方法
JP2005519941A (ja) 結核の管理のために有用な医薬組成物の製造方法
CN106456740B (zh) 抗微生物免疫调节
JP2023153868A (ja) 結核の感染リスクがある人に対する予防剤として、又は感染した結核患者を治療するための二次薬として使用する組成物
WO2003075825A2 (en) The method of treating tuberculosis
JP2006502090A (ja) Ｈｉｖ陽性の個体で予防を結核に提供している方法
US8153102B2 (en) Process for manufacturing pharmaceutical composition comprises of Mycobacterium w in the treatment of asthma (obstructive lung disease)
EP1368044B1 (en) Immunomodulator for the management of human immunodeficiency virus (hiv) disease/infection
AU2002225263B2 (en) Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection
CH451407A (fr) Procédé de préparation de vaccins antigènes somatiques
WO2003063896A1 (en) Process of preparing a pharmaceutical composition for immunity against tuberculosis in hiv positive individuals
AU2003202725A1 (en) Method of providing prophylaxis for tuberculosis in HIV positive individuals
WO2003075827A2 (en) Use of mycobacterium w in the treatment of asthama(obstructive lung disease)
Robson et al. Immunity in tuberculosis
AU2002225263A1 (en) Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection
Tran Molecular Factors that Influence BCG Vaccine Properties